TRIMETAZIDINE IS EFFECTIVE IN REHABILITATION OF PATIENTS AFTER HEART VALVE REPLACEMENT: THE RESULTS OF 1-YEAR RANDOMIZED CONTROLLED STUDY


I.R. Gaysin (1), A.S. Gazimzyanova (1,2), T.V. Sokolova (2), N.I. Maksimov (1), A.A. Galimova (2), M.A. Voronova (2), E.A. Chernykh (2), I.R. Poyarkina (2)

(1) SBEI HPE "Izhevsk State Medical Academy" of RMPH, Izhevsk; (2) BHCI UR "Republican Clinical Diagnostic Center" of MPH of Udmurt Republic, Izhevsk
It is known that a successful surgery for valvular heart disease increases life expectancy, reduces symptoms and improves cardiac function. Nevertheless, left ventricular dysfunction, heart failure, and impaired quality of life (QOL) may persist and worsen in the postoperative period. We hypothesized that metabolically active drug trimetazidine may improve symptoms and quality of life of patients after heart valve replacement. The study involved 150 patients with valvular heart disease at the age of 55,3 ± 3,2 years (58 % men) who were randomized 1:1 to were to either use the optimal standard therapy (vitamin K antagonists, angiotensin converting enzyme inhibitors/ angiotensin II receptor antagonists, β- blockers, diuretics, statins and digoxin – if indicated) or trimetazidine at a dose of 35 mg twice a day in addition to the traditional therapy 2-4 weeks after surgical replacement of the aortic (n = 84) or mitral (n = 66) valve. Significant baseline differences between the trimetazidine group and the control group were not observed. It was shown that long-term therapy with trimetazidine in patients with mechanical prosthetic aortic/mitral valve improves the clinical status and QoL. This study is the first evidence that trimetazidine may be new additional therapy of patients after heart valve replacement.

About the Autors


I.R. Gaysin – MD, Assoc. Prof at the Department of Hospital Therapy SBEI HPE "Izhevsk State Medical Academy" of RMPH; e-mail: igaisin@mail.ru
A.S. Gazimzyanova – rheumatologist at the department of valvular heart disease BHCI UR "Republican Clinical Diagnostic Center" of MPH of Udmurt Republic, postgraduate student at the Department of Hospital Therapy SBEI HPE "Izhevsk State Medical Academy" of RMPH
T.V. Sokolova- Head of the department of valvular heart disease BHCI UR "Republican Clinical Diagnostic Center" of MPH of Udmurt Republic
N.I. Maksimov- MD, Prof., Head of the Department of Hospital Therapy SBEI HPE "Izhevsk State Medical Academy" of RMPH
A.A. Galimova - rheumatologist at the department of valvular heart disease BHCI UR "Republican Clinical Diagnostic Center" of MPH of Udmurt Republic
M.A. Voronova - rheumatologist at the department of valvular heart disease BHCI UR "Republican Clinical Diagnostic Center" of MPH of Udmurt Republic
.A. Chernykh - rheumatologist at the department of valvular heart disease BHCI UR "Republican Clinical Diagnostic Center" of MPH of Udmurt Republic
I.R. Poyarkina- Head of Outpatient Department BHCI UR "Republican Clinical Diagnostic Center" of MPH of Udmurt Republic


Similar Articles


Бионика Медиа